Semaglutide is a synthetic analogue of glucagon-like peptide-1 (GLP-1), a 30-amino acid incretin hormone naturally released from intestinal L-cells in response to food intake. Semaglutide was engineered with specific modifications – a C18 fatty diacid chain attached via a linker – that enable strong albumin binding, dramatically extending its half-life to support once-weekly dosing in research applications.
Researchers have extensively studied Semaglutide for its interactions with the GLP-1 receptor, which is expressed in pancreatic beta cells, hypothalamic regions, the brainstem, and peripheral tissues. Research has examined its glucose-dependent stimulation of insulin secretion and suppression of glucagon, as well as its effects on gastric emptying and central appetite-regulating circuits. Studies have explored its influence on the mesolimbic reward system and food cue reactivity.
Preclinical and clinical research has generated extensive data on Semaglutide’s effects on glycemic control, body weight, and cardiovascular outcomes. Studies have also examined its potential neuroprotective properties and effects on neuroinflammation in animal models of neurodegenerative disease. More recent research has explored its potential in addiction models, including studies examining its effects on alcohol consumption behaviors in preclinical settings.
For research use only. Not for human consumption. Iron Prairie Labs products are intended for qualified researchers and laboratory use only.
